153939-24-3

Upstream product

• 122320-77-8 2-[N-methyl-N-(2-benzoxazolyl)-amino]ethanol 
• 60833-61-6 2-chloro-3-(4-hydroxyphenyl)propionic acid methyl ester 
• 1972-28-7 diethylazodicarboxylate 
• 615-18-9 2-chloro-1,3-benzoxazole 
• 5597-50-2 3-(4-hydroxyphenyl)propionic acid methyl ester 
• 153939-49-2 3-<4-<2-(benzoxazol-2-ylmethylamino)ethoxy>phenyl>propionic acid methyl ester 
• 122320-97-2 methanesulfonic acid 2-(benzooxazol-2-ylmethylamino)ethyl ester 

Relevant academic research and scientific papers

Heterocyclic compounds and their use in the treatment of Type-II diabetes

A compound of the formula A1 --X--(CH2)n --O--A2 --A3 --CO.R2 (I) or a tautomeric form thereof and/or a pharmaceutically acceptable salt thereof, and/or a pharmaceutically acceptable solvate thereof, wherein: A1 represents a substituted or unsubstituted aromatic heterocyclyl group; A2 represents a benzene ring having three optional substituents; A3 represents a moiety of formula --(CH2)m --CHR1 -- wherein R1 represents a halogen atom or a moiety of formula S(O)p A4 wherein A4 represents hydrogen, substituted or unsubstituted alkyl, aryl, aralkyl, alkylcarbonyl or an aromatic heterocyclyl group and p represents zero or an integer 1 or 2 and m represents zero or an integer in the range of from 1 to 5, or A3 represents a moiety of formula --CH=CR1 -- wherein R1 is as defined above; R2 represents OR3 wherein R3 represents hydrogen, alkyl, aryl or aralkyl, or R2 represents --NR4 R5 wherein R4 and R5 each independently represent hydrogen or alkyl or R4 and R5 together with the nitrogen atom to which they are attached form a heterocyclic ring; X represents O, S or NR wherein R represents a hydrogen atom, an alkyl group, an acyl group, an aralkyl group wherein the aryl moiety may be substituted or unsubstituted, or a substituted or unsubstituted aryl group; and n represents an integer in the range of from 2 to 6; a process for the preparation of such a compound, a pharmaceutical composition comprising such a compound and the use of such a compound and composition in medicine.

Non thiazolidinedione antihyperglycaemic agents. 1: α-Heteroatom substituted β-phenylpropanoic acids

The 5-benzylthiazolidine-2,4-dione moiety of insulin sensitising antidiabetic agents can be replaced by a range of α-heteroatom functionalised β-phenylpropanoic acids. α-Oxy-carboxylic acids show potent antidiabetic activity and one compound, the α-ethoxyacid 15 (SB 213068), is one of the most potent antihyperglycaemic agents yet reported.

benzyl>-2,4-thiazolidinediones as Potent Antihyperglycemic Agents

A series of -2,4-thiazolidinediones and benzyl>-2,4-thiazolidinediones was synthesized from the corresponding aldehydes.Compounds from the urea series, exemplified by 16, showed antihyperglycemic potency comparable with known agents of the type such as pioglitazone and troglitazone (CS-045).The benzoxazole 49, a cyclic analogue of 16, was a very potent enhancer of insulin sensitivity, and by modification of the aromatic heterocycle, an aminopyridine, 37, was identified as a lead compound from SAR studies.Evaluation of antihyperglycemic activity together with effects on blood hemoglobin content, to determine the therapeutic index, was performed in 8-day repeat administration studies in genetically obese C57 BI/6 ob/ob mice.From these studies, BRL 49653 (37) has been selected, on the basis of antihyperglycemic potency combined with enhanced selectivity against reductions in blood hemoglobin content, for further evaluation.